Mapi Pharma Granted United States Patent Covering Glatiramer Depot for Multiple Sclerosis
The patent covers a long acting depot formulation that enables monthly rather than daily treatment regimens for MS patients
NESS ZIONA, Israel, May 6, 2013 /PRNewswire/ –
Mapi Pharma Ltd. (Mapi), developer of complex bulk Active Pharmaceutical Ingredients
(APIs), generic and innovative intermediates, and finished dosage forms based on selected
drug delivery systems, announced today that the company has been granted a United States
patent for a long acting depot formulation of glatiramer acetate. The formulation is under
development as a once-a-month treatment for Multiple Sclerosis (MS). The existing
glatiramer acetate dosage form on the market today requires daily administrations (by
US Patent number 8,377,885 B2 is titled Depot Systems Comprising Glatiramer or
Pharmacologically Acceptable Salt Thereof. The glatiramer acetate depot formulation
described therein is to be injected once-a-month under the skin or into a muscle for a
prolonged release of the therapeutic agent.
“It is a bright day both for MS patients and Mapi Pharma. Today’s news strengthens
Mapi’s patent position, supports its business plan and advances the company one step
closer to bringing MS patients an improved drug to be administered once-a-month,” said
Mapi Pharma President & CEO Mr. Ehud Marom.
MS is a chronic, often disabling disease that attacks the central nervous system.
Symptoms include numbness in the limbs, paralysis and loss of vision. Symptoms are
unpredictable and differ from one person to another. The global market for MS
pharmaceuticals is estimated to be approximately US $10 billion.
Mapi Pharma (Mapi) is an international pharmaceutical company specializing in complex
bulk Active Pharmaceutical Ingredients (APIs), generic and innovative intermediates, high
development barrier generics and novel finished dosage forms based on selected drug
delivery systems. Mapi is built on strong chemical and pharmaceutical R&D capabilities, a
deep understanding of the global market and of regulatory needs and its ability to foster
local cooperation and enduring relationships in all of the countries in which it is
present. Mapi is dedicated to providing generic and innovative intermediates & APIs as
well as developing finished dosage forms – either to Mapi’s internal API program, as a
vertically integrated company, or generic, to other leading brands. Mapi is headquartered
in Israel. It has R&D facilities in Israel, China and Germany and is currently building an
API manufacturing site in Neot Hovav, Israel’s designated chemical park. The company has a
strong IP position, filing more than 20 patent applications for APIs and formulations in
less than three years of operation. For more information: http://www.mapi-pharma.com.
Press Contact: Marjie Hadad Media Liaison Mapi Pharma firstname.lastname@example.org +972-54-536-5220
SOURCE Mapi Pharma Ltd. (Mapi)